Rapport director granted 15,200 stock options
Rapport Therapeutics director Robert J. Perez received a grant of stock options for 15,200 shares of common stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Rapport Therapeutics director Robert J. Perez received a grant of stock options for 15,200 shares of common stock. The options have an exercise price of $35.21 per share and expire on June 10, 2036.
The shares underlying this option vest upon the earlier of June 10, 2027 or the date of the next Annual Meeting of Stockholders of Rapport Therapeutics, subject to his continued service on that vesting date. Following this grant, he holds 15,200 derivative securities directly.
Insider Trade Summary
Grant/Award: 15,200 shares
Grant/Award
1 txn
Insider
PEREZ ROBERT J
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 15,200 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 15,200 contracts (Direct)
Footnotes (1)
- F1. The shares underlying this option shall vest upon the earlier of (i) June 10, 2027 and (ii) the date of the next Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continued service on such vesting date.
Key Figures
Options granted: 15,200 shares
Exercise price: $35.21 per share
Underlying shares: 15,200 shares
+3 more
6 metrics
Options granted
15,200 shares
Stock Option (Right to Buy) grant to director
Exercise price
$35.21 per share
Exercise price of stock options
Underlying shares
15,200 shares
Common stock underlying the option
Expiry date
June 10, 2036
Option expiration date
Shares after grant
15,200 derivative securities
Total derivative holdings following transaction
Potential vesting date
June 10, 2027
Latest vesting date, earlier of this or next annual meeting
Key Terms
Stock Option (Right to Buy), exercise price, Annual Meeting of Stockholders, vesting, +1 more
5 terms
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
exercise price financial
"conversion_or_exercise_price: 35.2100"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
Annual Meeting of Stockholders financial
"the date of the next Annual Meeting of Stockholders of the Issuer"
vesting financial
"The shares underlying this option shall vest upon the earlier of (i) June 10, 2027"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
derivative securities financial
"derivativeTransactionCount: 1"
Financial contracts whose value is tied to the price or performance of another asset, such as a stock, bond, commodity, index, or currency; examples include options, futures and swaps. They matter to investors because they let you protect against price swings, bet on future moves or gain larger exposure with less upfront cash—like using a lever or insurance policy on an investment—so they can amplify gains and losses and help manage portfolio risk.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Rapport Therapeutics (RAPP) report in this Form 4 filing?
Rapport Therapeutics reported that director Robert J. Perez received a grant of stock options for 15,200 shares of common stock. These options were awarded at an exercise price of $35.21 per share and are part of his equity-based compensation from the company.
How many stock options did director Robert J. Perez receive from Rapport Therapeutics (RAPP)?
Robert J. Perez received stock options covering 15,200 shares of Rapport Therapeutics common stock. All 15,200 underlying shares are tied to this single grant, and his total derivative holdings following the transaction are 15,200, indicating this is his reported option position in this filing.
What is the exercise price of the stock options granted to the Rapport Therapeutics (RAPP) director?
The stock options granted to director Robert J. Perez carry an exercise price of $35.21 per share. This means he can purchase Rapport Therapeutics common stock at $35.21 for each option, subject to meeting the vesting conditions and exercising before the expiration date.
When do Robert J. Perez’s Rapport Therapeutics (RAPP) stock options vest?
The options vest upon the earlier of June 10, 2027 or the date of the next Annual Meeting of Stockholders of Rapport Therapeutics. Vesting is also conditioned on his continued service with the company through the applicable vesting date specified in this grant.
When do the stock options granted to the Rapport Therapeutics (RAPP) director expire?
The stock options granted to director Robert J. Perez expire on June 10, 2036. He must satisfy the vesting conditions and exercise any vested options before this expiration date, or they will lapse and no longer provide the right to buy company shares.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates